Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11337943 | AUCTA | Lacosamide pharmaceutical composition and dosage form thereof |
Jun, 2040
(16 years from now) |
Motpoly Xr is owned by Aucta.
Motpoly Xr contains Lacosamide.
Motpoly Xr has a total of 1 drug patent out of which 0 drug patents have expired.
Motpoly Xr was authorised for market use on 04 May, 2023.
Motpoly Xr is available in capsule, extended release;oral dosage forms.
Motpoly Xr can be used as treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.
The generics of Motpoly Xr are possible to be released after 05 June, 2040.
Drugs and Companies using LACOSAMIDE ingredient
Market Authorisation Date: 04 May, 2023
Treatment: Treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg
Dosage: CAPSULE, EXTENDED RELEASE;ORAL